Compare iShares MSCI China ETF (MCHI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI China ETF trades at $53.53, while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| MCHI | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $66.99 | $59.06 |
52-Week Low | $50.48 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $54.08, up 2.13% with a bullish technical signal from moving averages. The stock shows neutral momentum oscillators with RSI at 68.39 suggesting mild overbought conditions. Recent news highlights China's focus on AI infrastructure investment and export controls on technology sectors, creating both opportunities and regulatory uncertainties for China-focused ETFs.
The outlook remains cautiously optimistic given China's economic stabilization efforts and AI sector growth, though geopolitical tensions and value trap concerns present significant risks. Wall Street sentiment appears mixed with some analysts highlighting structural headwinds while others see potential in the technology sector rebound.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
